Domagrozumab
Jump to navigation
Jump to search
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | GDF-8 |
| Clinical data | |
| Other names | PF-06252616 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C6366H9826N1690O2008S46 |
| Molar mass | 143639.22 g·mol−1 |
Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.[1][2]
This drug was developed by Pfizer. Pfizer stopped development in 2018 after disappointing results in 2 human trials.[3]
References
[edit | edit source]- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Domagrozumab, American Medical Association.
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |